US92854B1098 - Common Stock
1.01 +0.01 (+1%)
VIVANI MEDICAL INC
NASDAQ:VANI (9/28/2023, 7:19:25 PM)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Vivani Medical, Inc. develops and commercializes drug and device implants that treat patients with chronic diseases with high unmet medical need. The company is headquartered in Emeryville, California and currently employs 50 full-time employees. The company went IPO on 2014-11-19. The firm develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. The company uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. NanoPortal implant technology's initial focus is on peptide therapeutics for the treatment of patients with metabolic diseases. The company operates through two segments: Biopharm Division and Neuromodulation Division. Its pipeline product candidates include NPM-119, NPM-159, NPM-139 and OKV-119. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. NPM-159 is in feasibility testing for the treatment of non-alcoholic steatohepatitis (NASH). The company is also in the development of neurostimulation systems to help patients recover critical body functions.
VIVANI MEDICAL INC
5858 Horton Street, Suite 280
Vivani Medical (VANI) disclosed in a regulatory filing on Thursday that director and 10% stakeholder William Gregg bought 53.3k shares of the company ranging between 93 and 94 cents for...
Here you can normally see the latest stock twits on VANI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.